In the large conference room of Xinming Pharmaceutical Company, another high platform was set up.
On the background board of the high platform was the signing ceremony of the joint venture between Xinming Pharmaceutical and Johnson Johnson.
Fu Xinming signed the contract with the CEO of Johnson Johnson. Both parties exchanged their signatures and took photos.
On the stage, the main leader of the province, Zhang Hengyuan, was present. Even Song He from the Provincial Food and Drug Administration could only stand by Edward's side.
For such a big project, just Song He's attendance didn't show how important it was.
Zhang Hengyuan held Fu Xinming's hand." President Fu, your Xinming Pharmaceuticals gave me a big surprise. You got four billion USD just like that!"”
Fu Xinming shook his head." Leader, we don't have four billion. We still have to pay taxes."”
Zhang Hengyuan looked at Fu Xinming in surprise.""Don't you know? Two days ago, Song He helped you submit a national-level application for a special list of major new drugs. It should have already reached the headquarters. There shouldn't be any problems.”
"As long as this is passed, then this year, Xinming Pharmaceuticals will receive a tax-free preferential policy. President Fu, the province is very supportive of you. Don't move the company's headquarters.”
Next year, when the new drug was put into production, he would be able to continuously obtain tax revenue and drive local employment. This was what Zhang Hengyuan valued more.
Many pharmaceutical companies 'representatives looked at Johnson Johnson's CEO enviously. They couldn't understand why they failed despite offering a high price.
The CEO of Johnson Johnson looked at Fu Xinming and Fu Liang. Many people probably didn't know that the Fu family was the biggest beneficiary.
The equity structure of Xinming Pharmaceutical was not complicated, but the rights and interests of this new drug did not completely belong to Xinming Pharmaceutical. Fortunately, the other rights and interests still belonged to the Fu family.
This time, the painkiller project would be separated and injected into a joint venture subsidiary.
The shares of this subsidiary were divided into three parts. Xinming Pharmaceutical held 23.5%, Johnson Johnson held 33%, Fu Liang's mother held 10%, and Fu Liang held 33.5%.
All of this was thanks to the supplementary agreement that his father had asked the shareholders to sign. He had to get 50% of the rights to the new drug that Fu Liang had developed.
The four billion USD that Johnson Johnson paid would also be divided into three portions, which would belong to Xinming Pharmaceutical, Fu Liang, and Fu Liang's mother.
Xinming Pharmaceuticals only received 1.4 billion USD, and the majority of it belonged to Fu Xinming.
The remaining 2.6 billion US dollars belonged to Fu Liang's family. If converted to RMB, it would be more than 10 billion!
The money would be paid in two portions. Two billion US dollars would be paid in a week, and another two billion US dollars would be paid after the third phase of the clinical trial was over.
If the third phase of clinical trials proved that the drug failed, all the money would have to be returned.
Fu Liang agreed to Johnson Johnson's request at that time because he could guarantee that this drug would never fail!
After celebrating with Johnson Johnson and the company's shareholders, Fu Liang returned to his parents 'house at night.
The two of them did not drink much during the dinner party. When they returned home, the father and son sat at the dining table and opened a few cans of beer.
"Son, Xinming Pharmaceuticals is finally on the fast track.”
Fu Xinming gulped down a mouthful of beer, and his face turned red.
If domestic drugs wanted to enter the European and American markets, the procedures would be very cumbersome, and it would be easy to be obstructed by the US's Food and Drug Administration.
These large pharmaceutical companies had a certain degree of influence on the Food and Drug Administration.
Moreover, after being certified by the US's Food and Drug Administration, there would not be too much obstruction in re-certification in Europe.
Therefore, working with Johnson Johnson was not just about obtaining a large sum of money, so that Xinming Pharmaceutical could quickly develop hair growth products and other drugs.
Moreover, this was just a knock on the door. As long as the door was opened, it would be easier for new drugs to enter the US and European markets in the future.
After that, there was no need for Xinming Pharmaceutical to cooperate with other pharmaceutical companies. They could develop their own drugs and have the strength to develop them.
This time, Johnson Johnson would represent the sales of Supainkiller in the overseas market. They would also rely on their experience to help Xinming Pharmaceutical set the price of Supainkiller to ensure the highest profit.
By borrowing Johnson Johnson's sales channels, Xinming Pharmaceutical's name quickly spread around the world.
It would be even easier to launch new drugs later.
If other big pharmaceutical companies wanted to cause trouble, Johnson Johnson would also solve it. After all, they also had their own interests.
Of course, Johnson Johnson didn't lose out either. First, they could get a third of the project's revenue. Second, one year before the patent protection expired, they would license the drug patent to Johnson Johnson, and the license fee would be calculated separately.
Johnson Johnson could become the second largest painkiller manufacturer after Xinming Pharmaceutical and maintain their leading position in the painkiller market.
"Dad, the business adjustment of our Xin Ming Pharmaceutical is about to end, right?”
Ever since Fu Liang developed the hair growth medicine and hair removal cream, Xinming Pharmaceutical's business had been adjusting.
They would purchase new production lines, carry out technological innovation, and stop using some unprofitable drugs.
Up until now, 80% of the medicine production had been stopped. Once some contracts were completed, they could all stop.
In any case, those broad-spectrum generics were not profitable. Most pharmaceutical companies could produce them, and the competition was too great.
This kind of medicine could make money. It could either be listed on the list of the medical insurance bureau, or it could be changed to a new name, packaged, and sold at a high price.
"It'll be almost done in two months. By then, the approval for the hair growth medicine should have come.”
Johnson Johnson actually wanted to license the hair growth medicine, but Fu Xinming didn't agree.
They weren't in a hurry to sell this hair growth medicine. They would first make it famous in the domestic market, and then the US Food and Drug Administration application would probably be approved.
At that time, Xinming Pharmaceutical's Sutenideng should have also started to be listed in Europe and the United States, so it would be a good time to develop together.
At worst, Johnson Johnson would become the sales agent, and the management would be more worry-free.
In any case, Xinming Pharmaceuticals would only sell the new special drug developed by his son in the future. In the future, Xinming Pharmaceuticals would become a new special drug research and development company.
In this way, the company's ability to resist risks would be stronger, and its profit margin would be higher, and its reputation would be higher.
However, the only drawback was that none of the products developed now could treat serious diseases, which meant that they could not treat those life-threatening diseases. This was an important factor in measuring the strength of a pharmaceutical company.
However, Fu Xinming was not in a hurry. He felt that with his son's talent, sooner or later, he would be able to develop a new drug that could treat major illnesses.
"Son, is there any progress on the new drug development? Even a pharmaceutical company like Johnson Johnson only releases one or two new drugs a year. The rest is just upgrading the formula and improving the process. Your speed is already very fast.”
"Dad, leave the research and development of the new drug to me." Fu Liang smiled.”
"Just wait and see. I'll soon surprise the global pharmaceutical companies again and let them know that we didn't successfully develop a new special drug by luck, but that we have the ability to develop new drugs that they can't imagine!”
This book comes from：m.funovel.com。